Assertio Q2 net product sales $30.7M, GAAP net loss $3.7M; reiterates FY guidance

Assertio Holdings, Inc.

2024-Q2 EPS reported -$0.09 revenue$63,574,000

Net product sales $30.7M vs $40.1M in Q2 2023; GAAP net loss $0.04/share vs income $0.13/share.
Rolvedon net sales $15.1M, up from $14.5M QoQ; Indocin $6.9M, down from $8.7M due to generic competition.
Adjusted EBITDA $5.0M vs $24.8M in Q2 2023; cash from operations $7.4M.
Cash & short-term investments $88.4M, up from $80.7M; debt $40.0M in 6.5% convertible notes due 2027.
FY 2024 guidance reaffirmed: net product sales $110-125M, adjusted EBITDA $20-30M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.